NTM Patient Care UK provides evidence to The Scottish Medicines Consortium (SMC) Committee in assessment of new NTM treatment.

Earlier this year, NTM Patient Care UK gave evidence to The Scottish Medicines Consortium (SMC) Committee assessing the use of nebulised liposomal amikacin (tradename Arikayce) in the treatment of some forms of pulmonary MAC NTM. After careful consideration of the evidence, the SMC accepted this medicine for use by NHS Scotland.  The decision was published on Monday 13th December 2021.

The relevant Detailed Advice Document can be found here and a link to the Decision Explained public information summary here.